Tell me more about this opportunity: FAP-targeted radioligand therapy (German programs with pediatric sarcoma...

FAP-Targeted Radioligand Therapy: Understanding This Emerging Opportunity for Marlo

Based on your treatment strategy document and current sarcoma research, let me explain what FAP-targeted radioligand therapy is and why it's being considered for Marlo.

---

What Is FAP-Targeted Radioligand Therapy?

The Basic Concept

FAP = Fibroblast Activation Protein, a protein found in the tumor's supporting tissue (stroma), not the cancer cells themselves.

How it works:

1. A radioactive tracer (ligand) is designed to bind specifically to FAP
2. The tracer is injected into the bloodstream
3. It travels to the tumor and attaches to FAP-expressing cells in the tumor stroma
4. The radioactivity delivers targeted radiation directly to the tumor microenvironment
5. This damages cancer-supporting cells and can slow tumor growth

Why This Matters for Spindle Cell Sarcomas

According to your documents and current sarcoma research:

• Spindle cell tumors often have prominent stromal components - meaning they rely heavily on supporting connective tissue
• FAP is highly expressed in sarcoma stroma - making these tumors potentially good candidates for FAP-targeting
• This is a "cold" tumor biology (limited immune infiltration) - FAP-targeting may work synergistically with immune-priming strategies like your planned peptide vaccine

---

The German Program Advantage

Your document specifically mentions "two German groups with pediatric sarcoma experience." Here's why Germany is leading this field:

Why German Centers?

Germany has been at the forefront of FAP-targeted radioligand therapy:

1. University of Heidelberg & University of Essen - pioneering FAP-PET imaging and therapeutic radioligands
2. Established pediatric protocols - they have experience treating children with sarcomas using FAP-targeting
3. Advanced imaging infrastructure - FAP-PET/CT scanners available (limited in US)
4. Regulatory pathway clarity - Germany's regulatory environment allows expanded access for pediatric cases

Key German Research Groups (Based on Literature)

The leading groups working with pediatric sarcomas include:

• Prof. Uwe Haberkorn's group (Heidelberg) - pioneering FAP-PET imaging
• Prof. Clemens Kratochwil's group (Essen/Heidelberg) - therapeutic FAP radioligands in solid tumors
• University Medical Center Freiburg - pediatric oncology with FAP experience

---

How FAP-Targeted Therapy Works in Practice

Step 1: FAP Imaging (Diagnostic)

Purpose: Confirm that Marlo's tumor actually expresses FAP before committing to therapy

Process:

• Injection of FAP-PET tracer (e.g., FAP-2286 or similar)
• PET/CT imaging to visualize FAP uptake in the tumor
• Quantification of SUV (standardized uptake value) to assess FAP expression level
• If positive: tumor "lights up" on imaging, confirming FAP expression

Timeline: 1-2 weeks for imaging and interpretation

Availability:

• ✅ Available in Germany (routine)
• ⚠️ Limited availability in US (mostly research settings)
• Consider: Mayo Clinic, Memorial Sloan Kettering, or other major centers may have access

Step 2: FAP-Targeted Radioligand Therapy (Therapeutic)

If FAP imaging is positive:

Radioligands being used:

• FAP-2286 (most common in pediatric cases)
• FAP-2286-Lu177 (lutetium-177 version - therapeutic)
• FAP-2286-Ac225 (actinium-225 version - higher energy, for resistant tumors)

Treatment protocol:

• Multiple injections over weeks/months (typically 3-6 cycles)
• Each injection delivers targeted radiation to FAP-expressing tissue
• Imaging between cycles to assess response
• Monitoring for side effects (bone marrow, kidney function)

Timeline: 2-4 months for complete treatment course

---

Clinical Evidence & Rationale for Marlo

Why This Could Work for Spindle Cell Sarcoma

From your documents and literature:

1. Stromal-dependent tumor biology - Spindle cell sarcomas have prominent myofibroblastic stroma (as noted in Marlo's pathology: "myofibroblastic origin")

2. FAP expression in sarcoma stroma - Research shows FAP is highly expressed in soft tissue sarcoma microenvironment

3. Synergy with other therapies - FAP-targeting can:

   • Work alongside EGFR-targeted therapy (afatinib)
   • Prime the tumor for immunotherapy (peptide vaccine)
   • Complement organoid-guided drug selection

4. Pediatric safety data emerging - German centers have treated children with sarcomas; toxicity profile appears manageable

Current Evidence Level

Important context: FAP-targeted radioligand therapy for pediatric sarcomas is:

• ✅ Established in Germany with growing case series
• ⚠️ Emerging in the US (mostly research/compassionate use)
• 🔬 Not yet standard of care in most US institutions
• 📊 Promising early data but not yet in major randomized trials

---

Practical Considerations for Marlo

Logistics & Access

Questions your team should explore:

1. "Which specific German centers have treated pediatric spindle cell sarcomas with FAP radioligands, and what are their current enrollment criteria?"

   • Why: Not all German centers may accept international patients; some may have specific age/disease restrictions

2. "What is the timeline for FAP imaging and therapy if we pursue this in Germany vs. seeking US-based access?"

   • Why: Travel logistics, insurance coverage, and treatment scheduling differ significantly

3. "Are there US centers (Mayo, MSK, Stanford, UCSF) currently offering FAP-PET imaging or radioligand therapy for pediatric sarcomas?"

   • Why: Might avoid international travel while still accessing cutting-edge therapy

4. "What are the insurance/payment considerations for treatment in Germany vs. US compassionate use programs?"

   • Why: International treatment can be expensive; some US programs may cover costs

Medical Sequencing Questions

1. "Should FAP imaging happen before or after the next cycle of systemic therapy (afatinib)?"

   • Why: Timing affects interpretation and treatment planning

2. "Can FAP-targeted therapy be combined with the organoid-guided drug selection and EGFR inhibition?"

   • Why: Understanding synergies vs. conflicts is critical

3. "What is the expected response timeline, and how will response be measured?"

   • Why: Need to know when to assess efficacy and adjust treatment

---

How This Fits Into Marlo's Overall Strategy

Your Current Plan (From Treatment Strategy Document)

Your team is considering:

• ✅ Afatinib (EGFR-targeted therapy)
• ✅ Organoid drug screening (personalized medicine)
• ✅ Peptide vaccine (immune priming)
• ✅ Possible CAR-T (St. Jude trial)
• ✅ FAP-targeted radioligand therapy (stromal targeting)

Potential Sequencing

One rational approach might be:

1. Phase 1 (Now): Afatinib + organoid-guided optimization
2. Phase 2 (Weeks 4-8): FAP imaging to confirm FAP expression
3. Phase 3 (If FAP+): FAP-targeted radioligand therapy (3-6 cycles)
4. Phase 4 (Parallel): Peptide vaccine development and administration
5. Phase 5 (Later): Consider CAR-T if needed, or continue maintenance therapy

Rationale: This sequence targets multiple tumor vulnerabilities:

• EGFR pathway (cancer cells)
• Tumor stroma (FAP-targeting)
• Immune system (vaccine + possible checkpoint inhibitors)

---

Key Advantages & Limitations